10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer

New England Journal of Medicine

Volumn 375, Issue 15, 2016, Pages 1415-1424

  Hamdy, Freddie C ^a   Donovan, Jenny L ^b,c   Lane, J Athene ^b   Mason, Malcolm ^f   Metcalfe, Chris ^b   Holding, Peter ^a   Davis, Michael ^b   Peters, Tim J ^b   Turner, Emma L ^b   Martin, Richard M ^b   Oxley, Jon ^d   Robinson, Mary ^h   Staffurth, John ^f   Walsh, Eleanor ^b   Bollina, Prasad ^j   Catto, James ^k   Doble, Andrew ^l   Doherty, Alan ⁿ   Gillatt, David ^e   Kockelbergh, Roger ^o   Kynaston, Howard ^g   Paul, Alan ^p   Powell, Philip ⁱ   Prescott, Stephen ^p   Rosario, Derek J ^k   Rowe, Edward ^e   Neal, David E ^a,m   more..

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c UNIVERSITY HOSPITALS BRISTOL NHS FOUNDATION TRUST   (United Kingdom)

^d NORTH BRISTOL NHS TRUST   (United Kingdom)

^e BRISTOL UROLOGICAL INSTITUTE   (United Kingdom)

^f CARDIFF UNIVERSITY   (United Kingdom)

^g CARDIFF AND VALE UNIVERSITY HEALTH BOARD   (United Kingdom)

^h ROYAL VICTORIA INFIRMARY   (United Kingdom)

ⁱ FREEMAN HOSPITAL   (United Kingdom)

^j UNIVERSITY OF EDINBURGH   (United Kingdom)

^k UNIVERSITY OF SHEFFIELD   (United Kingdom)

^l ADDENBROOKE S HOSPITAL   (United Kingdom)

^m UNIVERSITY OF CAMBRIDGE   (United Kingdom)

ⁿ QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^o UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

^p LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE DISTRIBUTION; AGED; ANTIGEN DETECTION; ARTICLE; CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER LOCALIZATION; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER STAGING; CANCER SURGERY; CLINICAL PROTOCOL; CONFORMAL RADIOTHERAPY; CONTROLLED STUDY; DISEASE COURSE; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT MONITORING; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; TUMOR BIOPSY; AGE; BLOOD; COMPARATIVE EFFECTIVENESS; COMPARATIVE STUDY; FOLLOW UP; KAPLAN MEIER METHOD; METASTASIS; MIDDLE AGED; MORTALITY; PROSTATECTOMY; PROSTATIC NEOPLASMS; WATCHFUL WAITING;

AGE FACTORS; AGED; COMPARATIVE EFFECTIVENESS RESEARCH; DISEASE PROGRESSION; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM METASTASIS; OUTCOME ASSESSMENT (HEALTH CARE); PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; WATCHFUL WAITING;

EID: 84991231538     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1606220     Document Type: Article

References (29)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016; 66: 7-30.
2. Holmberg L, Bill-Axelson A, Helgesen F, et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 2002; 347: 781-9.
3. Bill-Axelson A, Holmberg L, Garmo H, et al. Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med 2014; 370: 932-42.
4. Wilt TJ, Brawer MK, Jones KM, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012; 367: 203-13.
5. Donovan JL, Hamdy FC, Lane JA, et al. Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med 2016; 375:1425-37.
6. Lane JA, Donovan JL, Davis M, et al. Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial. Lancet Oncol 2014; 15: 1109-18.
7. Sydes MR, Stephens RJ, Moore AR, et al. Implementing the UK Medical Research Council (MRC) RT01 trial (ISRCTN 47772397): methods and practicalities of a randomised controlled trial of conformal radiotherapy in men with localised prostate cancer. Radiother Oncol 2004; 72: 199-211.
8. Mayles WPM, Moore AR, Aird EGA, et al. Questionnaire based quality assurance for the RT01 trial of dose escalation in conformal radiotherapy for prostate cancer (ISRCTN 47772397). Radiother Oncol 2004; 73: 199-207.
9. Mason MD, Moore R, Jones G, et al. Radiotherapy for prostate cancer: is it "what you do" or "the way that you do it"? A UK perspective on technique and quality assurance. Clin Oncol (R Coll Radiol) 2016; 28(9): e92-e100.
10. Andriole GL, Crawford ED, Grubb RL III, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360: 1310-9.
11. Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360: 1320-8.
12. Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet 2014; 384: 2027-35.
13. Turner EL, Metcalfe C, Donovan JL, et al. Contemporary accuracy of death certificates for coding prostate cancer as a cause of death: is reliance on death certification good enough? A comparison with blinded review by an independent cause of death evaluation committee. Br J Cancer 2016; 115: 90-4.
14. Williams NJ, Hill EM, Ng SY, et al. Standardisation of information submitted to an endpoint committee for cause of death assignment in a cancer screening trial - lessons learnt from CAP (Cluster randomised triAl of PSA testing for Prostate cancer). BMC Med Res Methodol 2015; 15: 6.
15. Roach M 3rd, Hanks G, Thames H Jr, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006; 65: 965-74.
16. Prostate Testing for Cancer and Treatment (ProtecT) Study: statistical analysis plan. Bristol, United Kingdom: University of Bristol, 2015 (http://hdl.handle.net/1983/14265b05-5d00-40b2-90c7-020db8ee725a).
17. Bauer P. Multiple testing in clinical trials. Stat Med 1991; 10: 871-89.
18. Shoag JE, Mittal S, Hu JC. Reevaluating PSA testing rates in the PLCO Trial. N Engl J Med 2016; 374: 1795-6.
19. Andriole GL, Crawford ED, Grubb RL III, et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst 2012; 104: 125-32.
20. Schröder FH, Hugosson J, Roobol MJ, et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012; 366: 981-90.
21. Heijnsdijk EA, de Carvalho TM, Auvinen A, et al. Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data. J Natl Cancer Inst 2015; 107: 366.
22. Volk RJ, Wolf AM. Grading the new US Preventive Services Task Force prostate cancer screening recommendation. JAMA 2011; 306: 2715-6.
23. Turner EL, Metcalfe C, Donovan JL, et al. Design and preliminary recruitment results of the Cluster randomised triAl of PSA testing for Prostate cancer (CAP). Br J Cancer 2014; 110: 2829-36.
24. Klotz L, Vesprini D, Sethukavalan P, et al. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol 2015; 33: 272-7.
25. Tosoian JJ, Mamawala M, Epstein JI, et al. Intermediate and longer-term outcomes from a prospective active-surveillance program for favorable-risk prostate cancer. J Clin Oncol 2015; 33: 3379-85.
26. Bokhorst LP, Alberts AR, Rannikko A, et al. Compliance rates with the Prostate Cancer Research International Active Surveillance (PRIAS) protocol and disease reclassification in noncompliers. Eur Urol 2015; 68: 814-21.
27. Graham J, Kirkbride P, Cann K, Hasler E, Prettyjohns M. Prostate cancer: summary of updated NICE guidance. BMJ 2014; 348: f7524.
28. Simpkin AJ, Tilling K, Martin RM, et al. Systematic review and meta-analysis of factors determining change to radical treatment in active surveillance for localized prostate cancer. Eur Urol 2015; 67: 993-1005.
29. Lane A, Metcalfe C, Young GJ, et al. Patient-reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments: study design, and baseline urinary, bowel and sexual function and quality of life. BJU Int 2016 July 14 (Epub ahead of print).